Erlocip (Erlotinib) 150 mg

Indicated for the treatment of:

• Non-Small Cell Lung Cancer (NSCLC):
  • First-line treatment for patients with EGFR activating mutations.
  • Maintenance treatment for stable disease.
  • Second or third-line treatment after chemotherapy failure.
• Pancreatic Cancer: In combination with Gemcitabine.

Strength: 150 mg tablet.

Standard Dosage (Lung Cancer): 150 mg once daily.

⚠️ CRITICAL ADMINISTRATION GUIDE:

• 🚫 Empty Stomach Only: Take at least 1 hour before or 2 hours after meals. Food increases drug exposure significantly, leading to severe toxicity.
• 🚬 Smoking Interaction: Smoking reduces plasma levels of Erlotinib by 50-60%. Smoking cessation is strongly advised.
• 💊 No PPIs: Avoid Omeprazole/Pantoprazole (they reduce drug absorption).

• Severe hepatic or renal impairment.
• Pregnancy (Category D) and breastfeeding.
• Severe hypersensitivity to Erlotinib.

Patients should expect:

• Acneiform Rash: Occurs in most patients. It is often a surrogate marker of efficacy (the rash means the drug is working).
• Diarrhea: Manage with Loperamide and hydration.
• Interstitial Lung Disease (ILD): Rare but serious. Report sudden coughing or fever immediately.
• Dry skin and brittle nails.